MEGAKARYOCYTES AND FIBROBLASTS - INTERACTIONS AS DETERMINED IN NORMAL HUMAN BONE-MARROW SPECIMENS

被引:15
作者
SCHMITZ, B
THIELE, J
KAUFMANN, R
WITTE, O
WICKENHAUSER, C
KUHNREGNIER, F
FISCHER, R
机构
[1] UNIV COLOGNE,INST PATHOL,D-50924 COLOGNE,GERMANY
[2] UNIV COLOGNE,CARDIAC SURG CLIN,D-50924 COLOGNE,GERMANY
关键词
HUMAN BONE MARROW; FIBROBLASTS; MEGAKARYOCYTES; CELL TO CELL CONTACT; PDGF; TGF-BETA-1;
D O I
10.1016/0145-2126(95)00035-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An in vitro study was performed to investigate possible interactions between megakaryocytes and bone marrow fibroblasts, both obtained from healthy donors. We were able to demonstrate that the proliferation of fibroblasts increased significantly by co-culturing these cells with megakaryocytes for 6 days. Addition of neutralizing antibodies for PDGF and TGF beta(1), caused a significant reduction of fibroblast growth. Inhibition of cell to cell contacts via tissue culture inserts generated a conspicuous impairment of fibroblast proliferation compared with megakaryocyte-fibroblast co-cultures, where contact was allowed. Hence, our findings suggest that a close spatial relationship between megakaryocytes and fibroblasts is needed for the activation of growth in normal human bone marrow. Neighbouring of megakaryocytes and fibroblasts seems to be necessary in order to achieve a certain threshold of local growth factor concentration. Our results are in keeping with the assumption that PDGF end TGF beta(1) are secreted by normal human megakaryocytes in very low concentrations and promote significantly fibroblast proliferation.
引用
收藏
页码:629 / 637
页数:9
相关论文
共 43 条
[1]   GROWTH-FACTORS AND REGULATION OF CELL-GROWTH [J].
ANTONIADES, HN ;
OWEN, AJ .
ANNUAL REVIEW OF MEDICINE, 1982, 33 :445-463
[2]  
AVRAHAM H, 1992, BLOOD, V80, P1679
[3]   A REVERSIBLE DEFECT OF PLATELET PDGF CONTENT IN MYELOPROLIFERATIVE DISORDERS [J].
BAGLIN, TP ;
PRICE, SM ;
BOUGHTON, BJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (04) :483-486
[4]  
BERNABEI PA, 1986, BRIT J HAEMATOL, V63, P353
[5]   MYELOFIBROSIS IN CHRONIC MYELOPROLIFERATIVE DISORDERS - INCIDENCE AMONG SUBTYPES ACCORDING TO THE HANNOVER CLASSIFICATION [J].
BUHR, T ;
GEORGII, A ;
CHORITZ, H .
PATHOLOGY RESEARCH AND PRACTICE, 1993, 189 (02) :121-132
[6]  
BURKHARDT R, 1984, PATHOL RES PRACT, V179, P131
[7]   BONE-MARROW IN MEGAKARYOCYTIC DISORDERS [J].
BURKHARDT, R .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1988, 2 (04) :695-733
[8]   PLATELET FACTOR-4 EXCRETION IN MYELOPROLIFERATIVE DISEASE - IMPLICATIONS FOR THE ETIOLOGY OF MYELOFIBROSIS [J].
BURSTEIN, SA ;
MALPASS, TW ;
YEE, E ;
KADIN, M ;
BRIGDEN, M ;
ADAMSON, JW ;
HARKER, LA .
BRITISH JOURNAL OF HAEMATOLOGY, 1984, 57 (03) :383-392
[9]  
CAENAZZO A, 1989, ACTA HAEMATOL-BASEL, V81, P131
[10]  
CASTROMALASPINA H, 1981, BLOOD, V57, P781